Following Richard Rubino’s last AERI Sell transaction on November 01, 2013, the stock climbed by 49.0%. In addition to Richard Rubino, one other AERI executive reported Sell trades in the last month.
Based on Aerie Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $2.42 million and GAAP net loss of $55.02 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $28.43 million. Currently, Aerie Pharma has an average volume of 194.7K. The Company has a Price to Book ratio of 12.1534.
Based on 6 analyst ratings, the analyst consensus is Strong Buy with an average price target of $86.33, reflecting a 45.3% upside.
The insider sentiment on Aerie Pharma has been negative according to 31 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.